Following Its Recent Approval in the United States and Europe for Osteoporosis, Prolia Will Garner Sales of More than $500 Million in 2019

Tuesday, July 6, 2010 General News
Email Print This Page Comment
Font : A-A+

Prolia's Uptake Will Be Constrained by Its Premium Price and the Increasing Availability of Generic Drugs, According to Findings from Decision Resources

For more information, contact:

Decision Resources, Inc.

Christopher Comfort

781-296-2597

ccomfort@dresources.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook